LYBLOQEM Trademark

Trademark Overview


On Wednesday, February 26, 2025, a trademark application was filed for LYBLOQEM with the United States Patent and Trademark Office. The USPTO has given the LYBLOQEM trademark a serial number of 99057068. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, March 5, 2026. This trademark is owned by Pfizer Inc.. The LYBLOQEM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
lybloqem

General Information


Serial Number99057068
Word MarkLYBLOQEM
Filing DateWednesday, February 26, 2025
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, March 5, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 3, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, February 26, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192
US

Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10001-2192
US

Trademark Events


Event DateEvent Description
Wednesday, February 26, 2025NEW APPLICATION ENTERED
Wednesday, February 26, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 26, 2025APPLICATION FILING RECEIPT MAILED
Monday, May 5, 2025ASSIGNED TO EXAMINER
Monday, May 5, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 28, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 3, 2025PUBLISHED FOR OPPOSITION
Tuesday, June 3, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 7, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sunday, January 18, 2026ASSIGNED TO EXAMINER
Friday, January 30, 2026TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 30, 2026ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 30, 2026TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 30, 2026TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, March 5, 2026SOU TEAS EXTENSION RECEIVED
Thursday, March 5, 2026SOU EXTENSION 1 FILED
Thursday, March 5, 2026SOU EXTENSION 1 GRANTED
Friday, March 6, 2026NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED